PMID- 24378675 OWN - NLM STAT- MEDLINE DCOM- 20140715 LR - 20231011 IS - 1097-6868 (Electronic) IS - 0002-9378 (Print) IS - 0002-9378 (Linking) VI - 210 IP - 6 DP - 2014 Jun TI - Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women. PG - 561.e1-6 LID - S0002-9378(13)02247-3 [pii] LID - 10.1016/j.ajog.2013.12.036 [doi] AB - OBJECTIVE: To characterize adverse events (AEs) after hepatitis A vaccines (Hep A) and hepatitis A and hepatitis B combination vaccine (Hep AB) in pregnant women reported to the Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system. STUDY DESIGN: We searched VAERS for AEs reports in pregnant women who received Hep A or Hep AB from Jan. 1, 1996-April 5, 2013. Clinicians reviewed all reports and available medical records. RESULTS: VAERS received 139 reports of AEs in pregnant women; 7 (5.0%) were serious; no maternal or infant deaths were identified. Sixty-five (46.8%) did not describe any AEs. For those women whose gestational age was available, most were vaccinated during the first trimester, 50/60 (83.3%) for Hep A and 18/21 (85.7%) for Hep AB. The most common pregnancy-specific outcomes following Hep A or Hep AB vaccinations were spontaneous abortion in 15 (10.8%) reports, elective termination in 10 (7.2%), and preterm delivery in 7 (5.0%) reports. The most common nonpregnancy specific outcome was urinary tract infection and nausea/vomiting with 3 (2.2%) reports each. One case of amelia of the lower extremities was reported in an infant following maternal Hep A immunization. CONCLUSION: This review of VAERS reports did not identify any concerning pattern of AEs in pregnant women or their infants following maternal Hep A or Hep AB immunizations during pregnancy. CI - Published by Mosby, Inc. FAU - Moro, Pedro L AU - Moro PL AD - Immunization Safety Office, Division Of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA. FAU - Museru, Oidda I AU - Museru OI AD - Immunization Safety Office, Division Of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA. FAU - Niu, Manette AU - Niu M AD - Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, MD. FAU - Lewis, Paige AU - Lewis P AD - Immunization Safety Office, Division Of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA. FAU - Broder, Karen AU - Broder K AD - Immunization Safety Office, Division Of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA. LA - eng GR - CC999999/Intramural CDC HHS/United States PT - Journal Article DEP - 20131227 PL - United States TA - Am J Obstet Gynecol JT - American journal of obstetrics and gynecology JID - 0370476 RN - 0 (Viral Hepatitis Vaccines) SB - IM MH - Abortion, Spontaneous/epidemiology MH - Adult MH - *Adverse Drug Reaction Reporting Systems MH - Female MH - Hepatitis A/*immunology MH - Hepatitis B/*immunology MH - Humans MH - Infant, Newborn MH - Pregnancy MH - Premature Birth/epidemiology MH - United States/epidemiology MH - Urinary Tract Infections/epidemiology MH - Viral Hepatitis Vaccines/*adverse effects PMC - PMC6500450 MID - NIHMS1025291 OTO - NOTNLM OT - hepatitis A hepatitis B combined vaccine OT - hepatitis A vaccine OT - pregnancy OT - surveillance OT - vaccine safety COIS- Disclosure: the authors report no conflict of interest EDAT- 2014/01/01 06:00 MHDA- 2014/07/16 06:00 PMCR- 2019/05/04 CRDT- 2014/01/01 06:00 PHST- 2013/09/16 00:00 [received] PHST- 2013/11/20 00:00 [revised] PHST- 2013/12/26 00:00 [accepted] PHST- 2014/01/01 06:00 [entrez] PHST- 2014/01/01 06:00 [pubmed] PHST- 2014/07/16 06:00 [medline] PHST- 2019/05/04 00:00 [pmc-release] AID - S0002-9378(13)02247-3 [pii] AID - 10.1016/j.ajog.2013.12.036 [doi] PST - ppublish SO - Am J Obstet Gynecol. 2014 Jun;210(6):561.e1-6. doi: 10.1016/j.ajog.2013.12.036. Epub 2013 Dec 27.